Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-06-30

Study Completion Date

2004-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intensive chemotherapy is often associated with low platelet counts often requiring platelet transfusions to maintain platelet counts. In previous clinical studies administration of rhTPO has been demonstrated to increase platelet counts.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma

NCT00004123

Sarcoma

COMPLETED PHASE1

Combination Chemotherapy in Treating Patients With Sarcoma

NCT00662233

Ovarian Cancer Sarcoma

COMPLETED EARLY_PHASE1

Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors

NCT00002508

Extragonadal Germ Cell Tumor Ovarian Cancer Testicular Germ Cell Tumor

COMPLETED PHASE1/PHASE2

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

NCT00002948

Unspecified Adult Solid Tumor, Protocol Specific

TERMINATED PHASE1

Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

NCT00002950

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate the effectiveness of intravenous rhTPO vs. placebo as primary prophylaxis in reducing the cumulative proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia (platelet count \<15,000) during the first four study cycles. To evaluate the severity and duration of thrombocytopenia and neutropenia associated with rhTPO prophylaxis, the impact of rhTPO prophylaxis on health economics/cost effectiveness, and patient quality of life. To assess the safety of multiple IV doses of rhTPO.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rhTPO

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed new diagnosis of moderate or high-grade sarcoma (except leiomyosarcoma of gastrointestinal origin)
* Must have high risk disease by American Joint Committee on Cancer (AJCC) Staging System Stage IIC, III, or IV
* Must have recovered from surgery for a minimum of 2 weeks
* Must be scheduled for a minimum of 4 cycles of AI therapy
* Must be 13 years or older
* Must have ECOG performance status of 0, 1, or 2.
* Must have life expectancy of at least 12 weeks.
* Left ventricular ejection fraction must be more than 50%.
* Laboratory data within normal limits.

Exclusion Criteria

* Prior front-line standard or experimental therapy for sarcoma
* History of bone marrow and or peripheral blood progenitor cell transplantation
* Prior pelvic radiation or radiation therapy to more than 25% of bone marrow reserves
* Prior treatment with megakaryocyte growth and differentiation factor
* Prior treatment with rhTPO
* History of platelet disorder
* History of myocardial infarction, stroke, pulmonary embolism, or deep vein thrombosis within the past 12 months
* Pregnant or lactating women
* Use of anticoagulants such as coumadin, heparin, etc.
* Known HIV or hepatitis

Minimum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes